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OBJECTIVE—Regulatory T-cells (Tregs) recognizing islet au-
toantigens are proposed as a key mechanism in the maintenance
of self-tolerance and protection from type 1 diabetes. To date,
however, detailed information on such cells in humans, and
insight into their mechanisms of action, has been lacking. We
previously reported that a subset of CD4 T-cells secreting high
levels of the immunosuppressive cytokine interleukin-10 (IL-10)
is signiﬁcantly associated with late onset of type 1 diabetes and
is constitutively present in a majority of nondiabetic individuals.
Here, we test the hypothesis that these T-cells represent a
naturally generated population of Tregs capable of suppressing
proinﬂammatory T-cell responses.
RESEARCH DESIGN AND METHODS—We isolated and
cloned islet-speciﬁc IL-10–secreting CD4
 T-cells from nondia-
betic individuals after brief ex vivo exposure to islet autoantigens
using cytokine capture technology and examined their pheno-
type and regulatory potential.
RESULTS—Islet-speciﬁc IL-10
 CD4 T-cells are potent suppres-
sors of Th1 effector cells, operating through a linked suppression
mechanism in which there is an absolute requirement for the
cognate antigen of both the regulatory and effector T-cells to be
presented by the same antigen-presenting cell (APC). The regu-
latory T-cells secrete perforin and granzymes, and suppression is
associated with the speciﬁc killing of APCs presenting antigen to
effector T-cells.
CONCLUSIONS—This hitherto undescribed population of islet
autoantigen–speciﬁc Tregs displays unique characteristics that
offer exquisite speciﬁcity and control over the potential for
pathological autoreactivity and may provide a suitable target
with which to strengthen -cell–speciﬁc tolerance. Diabetes 59:
1451–1460, 2010
T
here is now overwhelming evidence from both
mice and humans that regulatory T-cells (Tregs)
play a key role in the process of controlling the
expansion of pathogenic autoreactive T-cells
and that defects in this key cell population can lead to the
development of autoimmune disease including type 1
diabetes (1–4). A view has therefore emerged that in the
majority of individuals for the majority of life, destructive
autoimmunity is held in check by populations of Tregs,
recognizing autoantigens and responding through a variety
of regulatory pathways (5–8).
Given the apparent importance of this cell type in
promoting self-tolerance, there has been much interest in
investigating whether strategies to increase the number or
functional potency of Tregs are capable of inﬂuencing the
progression of autoimmune diseases such as type 1 diabe-
tes. Indeed, numerous studies in animal models have
demonstrated that such strategies are able not only to
prevent the onset of type 1 diabetes but also to reverse
established diabetes, making them a logical target for
intervention strategies in humans (9–13). Critically, these
studies highlighted the importance of antigen speciﬁcity:
islet-speciﬁc Tregs have far greater potency than those
derived from polyclonal populations. This presents a sub-
stantial challenge to translating advances in our under-
standing of Treg biology into immunotherapy for human
type 1 diabetes, because the literature on the natural
repertoire of human islet antigen–speciﬁc Tregs that may
contribute to the tolerant state in vivo is scant.
In recent years, we have developed approaches that
allow the functional interrogation of human autoreactive
T-cells directly ex vivo for their ability to respond to islet
autoantigens (14,15). In a previous study, we reported the
existence of a population of islet autoreactive CD4 T-cells
that produce the signature immunosuppressive cytokine
interleukin-10 (IL-10) after brief coculture with naturally
processed and presented epitopes of proinsulin and IA-2
(16). Of note, such cells were frequently found in nondia-
betic individuals, and when present in patients, they
primarily segregated with a signiﬁcantly older age of
onset. We reasoned that such cells could have regulatory
properties, because they were associated with both the
absence and delayed onset of disease.
The present study tests this hypothesis. We isolated and
cloned CD4
 T-cells secreting IL-10 after brief ex vivo
exposure to islet autoantigens. As subjects, we elected to
use islet autoantibody–negative nondiabetic individuals,
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would be most operative. We ﬁnd that the islet-speciﬁc
IL-10–secreting CD4
 T-cells are potent suppressors of
proinﬂammatory effector Th1 cells, of the type believed to
mediate islet -cell destruction. Surprisingly, despite the
cells’ IL-10 production, we ﬁnd that their primary modus
operandi in vitro is the speciﬁc destruction of antigen-
presenting cells presenting peptides from islet autoanti-
gens. Our study represents an unequivocal demonstration
of autoantigen-speciﬁc Tregs in human type 1 diabetes and
provides a novel platform for the development of strate-
gies to promote their development.
RESEARCH DESIGN AND METHODS
Subjects. Fresh heparinized blood samples were obtained from 11 healthy
nondiabetic control subjects with no family history of type 1 diabetes. Ethical
approval for this study was granted by the local Ethics Committee and
informed consent obtained.
Antigens and synthetic peptides and cytokine ELISpot. Previously
identiﬁed peptides, representing naturally processed and presented epitopes
of IA-2 and proinsulin (16,17), and a set of overlapping peptides encompassing
the sequence of human insulin were synthesized by Keck Biotechnology
Resource Laboratory, Yale University. Tetanus toxoid was obtained from
Pasteur Merieux (Maidenhead, U.K.); hemagglutinin, from Solvay Pharmaceu-
ticals, Inc. (Marietta, GA); and human insulin, from Sigma Chemical Corpo-
ration (Poole, U.K.). Enzyme-linked immunosorbent spot (ELISpot) assays for
the detection of IL-10–producing T-cells were performed and analyzed as
previously described (16).
Isolation and cloning of IL-10–secreting CD4
 T-cells. IL-10–secreting
CD4
 T-cells were isolated using the Miltenyi IL-10 secretion, detection, and
enrichment kit following the manufacturer’s protocol (Miltenyi Biotec, Surrey,
U.K.). Cells were labeled with monoclonal anti-CD3, -CD4, and -CD14 anti-
bodies and 7-aminoactinomycin D (7-AAD; Merck Chemical Ltd., Nottingham,
U.K.) and analyzed on a MoFlo ﬂow cytometer (Cytomation Bioinstruments,
Freiburg, Germany), and single, viable, IL-10–secreting T-cells were deposited
into the wells of a 96-well tissue culture plate. Single cells were expanded by
the addition of mixed-donor irradiated peripheral blood mononuclear cells
(PBMCs; 10
5/well), phytohemagglutinin-L (4 g/ml; Biostat Diagnostic Sys-
tems, Stockport, U.K.), and human recombinant IL-15 (10 ng/ml; Peprotech,
London, U.K.) in 200 l/well complete media (X-Vivo15  5% pooled human
AB serum; BioWhittaker) and tested for antigen speciﬁcity. Antigen-speciﬁc
clones were restimulated every 21–28 days, and human recombinant IL-15 (10
ng/ml; Peprotech) was added at day 3 and as required during expansion. T-cell
clones were subjected to a maximum of three cycles of stimulation. T-cell
clones were used for the experiments described below when fully rested, a
minimum of 21 days after stimulation.
Characterization of IL-10–secreting T-cell clones. IL-10 and tumor ne-
crosis factor- (TNF-) secretion by T-cell clones was measured by ELISA
(ImmunoTools, Friesoythe, Germany); all other cytokines were measured by
multiplex bead array (Millipore Ltd., Watford, U.K.) on the Luminex 100
LabMAP System (Luminex Corporation, Oosterhout, The Netherlands). Anal-
ysis of cytokine production by intracellular ﬂow cytometry was performed as
previously described (18).
T-cell clones was studied by ﬂow cytometry, using anti-CD4, -CD3, CD69,
–HLA-DR, -CD39, –glucocorticoid-induced TNF receptor (GITR), -CD62L -4
integrin, and -7 integrin antibodies (BD Biosciences, Oxford, U.K.); anti–
inducible costimulator (ICOS) antibody (Biolegend, San Diego, CA); and
anti-CD25 (AbD Serotec, Oxford, U.K.). FoxP3 staining was performed using
the eBioscience anti-human Foxp3 Staining Set (Insight Biotechnology, Wem-
bley, U.K.), and granzyme and perforin expression were detected using BD
Biosciences staining sets, following the manufacturer’s instructions. Flow
cytometry was performed on a FACSCalibur or FACSAria (BD Biosciences)
and data were analyzed using FlowJo software (TreeStar, Ashland, OR).
Suppression assays. Suppression assays were performed through coculture
of putative regulatory T-cell clones with effector populations and antigen-
presenting cells (APCs) that had been differentially labeled with intracellular
ﬂuorescent dyes carboxyﬂuorescein diacetate, succinimidyl ester (CFSE) and
CellTrace Far Red DDAO-SE (DDAO) (Invitrogen, Paisley, U.K.). Autologous
suppression assays were established in 96-well plates with 1  10
5 CFSE-
labeled PBMCs/well  3  10
4 DDAO-labeled Treg clone. To facilitate further
analysis of the mechanisms of suppression, a panel of CD4
 Th1 clones
speciﬁc for recall antigens was generated as detailed in supplementary Table
1, available in an online appendix at http://diabetes.diabetesjournals.org/
content/early/2010/03/10/db09-0503/suppl/DC1. Clonal suppression assays
were established in 96-well plates with 3  10
4 CFSE-labeled clone cells, 1 
10
5 DDAO-labeled irradiated (3,000 rad) PBMCs as a source of antigen
presenting cells  3  10
4 DDAO-labeled Treg clone. To study the role of
cytokines in suppression, anti–IL-10R (clone 37607.11), anti–transforming
growth factor-1,2,3 (TGF-1,2,3; clone 111) (both R&D Systems, Abingdon,
U.K.), and mouse IgG1 isotype control (clone MOPC31C; Sigma Chemical
Corporation) antibodies were added to the cultures to a ﬁnal concentration of
10 g/ml. Transwell assays were established in 24-well plates (Costar,
Corning, NY) using 3  10
5 CFSE-labeled responder clone, 1  10
5 DDAO-
labeled irradiated PBMCs, and 3  10
5 DDAO-labeled Treg clones per well as
indicated. Percentage suppression was calculated as previously described
(19).
Cytotoxicity assay. Autologous PBMCs were labeled with either 0.1 or 1
mol/l CFSE and incubated in complete media at 1  10
6/ m lf o r3ha t37°C
with 25 g/ml peptide (0.1 mol/l labeled cells) or peptide diluent (DMSO; 1
mol/l labeled cells). Unbound peptide was removed by extensive washing,
target populations were combined at a ratio of 1:1, and 10
5 PBMCs were
incubated in the presence or absence of 10
5 resting Treg clones. After
incubation for 16 h at 37°C, cells were stained with anti-CD4, anti-CD14, and
anti-CD19 ﬂuorochrome-labeled antibodies (BD Biosciences) and 7-AAD and
analyzed by ﬂow cytometry, and percentage speciﬁc killing was calculated as
follows: 100  [(% peptide-labeled targets in absence of Tregs  % peptide-
labeled targets in absence of Tregs)/% peptide-labeled targets in absence of
Tregs]  100. In experiments using Epstein-Barr virus B-cell lines, target
populations were pulsed with peptide as described above, and killing was
assessed by calculating the percentage of 7-AAD
 cells. To assess the role of
the granzyme/perforin and Fas/Fas ligand (FasL) pathways in killing, cells
FIG. 1. Representative IL-10 responses to islet antigen peptides by
PBMCs from nondiabetic individuals stimulated with (A) insulin
B11–30 peptide compared with (B) peptide diluent alone in nondia-
betic individual M.H.; (C) IA-2 709–736 peptide compared with (D)
peptide diluent alone in nondiabetic individual R.A. E and F: Isolation
of IL-10–secreting cells by cytokine secretion assay. Plots represent
ﬂow cytometric analysis of magnetically enriched IL-10–secreting cells
from M.H. stimulated with insulin B11–30 peptide (E) compared with
background response to (F) diluent alone.
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(ConA; 100 nmol/l; Sigma Chemical), and anti-CD95L antibody (1 g/ml ZB4;
Immunotech, Marseilles, France).
Single-cell multiplex RT-PCR. Multiplex RT-PCR was performed on single
IL-10–secreting CD4 T-cells isolated from fresh PBMC preparations after
coculture with islet autoantigen as described above for cloning, based on the
technique described by Kelso et al. (20), using the primer pairs detailed in
supplementary Table 2. The frequency of expression of cytotoxic molecules in
different groups was compared by 	
2 analysis.
RESULTS
Detection and cloning of islet peptide–speciﬁc IL-10–
secreting T-cells from nondiabetic individuals. We
ﬁrst examined IL-10 responses to a panel of naturally
processed IA-2 and proinsulin peptides and a set of
overlapping peptides encompassing the insulin molecule
in a group of healthy nondiabetic individuals (n 
 11).
Using a highly sensitive and speciﬁc cytokine ELISpot, we
found that the majority of individuals (8/11, 72%) mounted
a signiﬁcant IL-10 response (insulin sensitivity index 3)
to at least one peptide (data not shown), consistent with
our previous work (16). Individuals with positive re-
sponses by ELISpot were recalled a minimum of 1 month
later, and IL-10–secreting CD4 T-cells were detected,
isolated by sensitive cytokine secretion assay, and imme-
diately single-cell sorted by ﬂow cytometry. The cytokine
secretion assay conﬁrmed the reproducible detection of
IL-10–secreting, islet peptide–speciﬁc CD3
CD4
 T-cells
in nondiabetic individuals (Fig. 1). Cloning was initiated
after brief (48 h) culture with antigen and was carried out
in the absence of any IL-10 biasing culture conditions.
T-cell clones speciﬁc for insulin B11–30 (clone MHB10.3)
and IA-2 709–736 (clone RAR5.3) were isolated from
nondiabetic individuals, M.H. (age 27 years; HLA-
DRB1*0301-DRB1*0404) and R.A. (age 27 years; HLA-
DRB1*0101-DRB1*0407), respectively. Both clones
produced large amounts of IL-10 (1 ng/ml), in response
to submicrogram doses of the peptide used in their isola-
tion (Fig. 2A).
Phenotypic analysis of IL-10–secreting islet-speciﬁc
T-cells. Analysis of cultures stimulated with suboptimal
doses of peptide demonstrated that both clones have a
similar cytokine secretion proﬁle, producing large
amounts of IL-10, IL-13, -interferon (IFN-), and IL-5 but
little or no IL-2, IL-4, TNF-, or IL-1 (Fig. 2B). A similar
cytokine secretion proﬁle was seen when MHB10.3 was
incubated with whole recombinant insulin (Fig. 2C). Anal-
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FIG. 2. Cytokine production proﬁles of islet-speciﬁc T-cell clones. A: MHB10.3 (open symbols) and RAR5.3 (closed symbols) were stimulated with
insulin B11–30 and IA-2 709–736, respectively, in the presence of autologous irradiated PBMCs, and IL-10 production was measured by
enzyme-linked immunosorbent assay after 3 days. B: Cytokine production by MHB10.3 (open bars) and RAR5.3 (closed bars) clones cultured as
above with suboptimal doses of peptide (1 g/ml) and by (C) MHB10.3 stimulated with whole recombinant insulin (100 g/ml) in the presence
of autologous irradiated dendritic cells. Cytokines were measured in 3-day supernatants by multiplex bead technology. D: Cytokine production
by MHB10.3 was assessed by ﬂow cytometry for intracellular synthesis of IL-10, IL-13, and IFN- after stimulation with plate-bound anti-CD3 and
soluble anti-CD28 antibodies for 2 days.
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when activated and producing cytokines, the same cells
produce IL-10, IFN-, and IL-13 (Fig. 2D). The HLA class II
restriction of the clones was investigated using monoclo-
nal antibodies that block HLA-DR or HLA-DQ and partially
HLA-matched irradiated PBMCs. These experiments dem-
onstrated that clone MHB10.3 was restricted by HLA-DR3
(B1*0301) and clone RAR5.3, by HLA-DR4 (DRB1*0407)
(data not shown).
Expression of activation and regulatory T-cell markers
on islet-speciﬁc T-cells was assessed by ﬂow cytometry. A
small number of resting IL-10–secreting islet-speciﬁc
clone cells (21 days after peptide stimulation) expressed a
low level of CD69 (14.4 and 7.5% for RAR5.3 and MHB10.3,
respectively), whereas much higher proportions ex-
pressed HLA-DR (94.6 and 60.4%), CD25 (99.8 and 92.8%),
FoxP3 (97.5 and 61.9%), CD39 (100 and 99.8%), and ICOS
(92 and 97.2%); lower levels of GITR (42.2 and 23.4%) and
CD62L (10.5 and 18.7%); and variable amounts of CD127
(32.7 and 64.1%) (supplementary Fig. 1). In addition, both
MHB10.3 and RAR5.3 expressed both 4 and 7 integrins
(supplementary Fig. 2), which were absent on the TT-speciﬁc
RATT6 and HA-speciﬁc RAHA5 Th1-type T-cell clones.
Regulatory potential of IL-10–secreting islet-speciﬁc
T-cells. To investigate the regulatory potential of IL-10–
secreting islet-speciﬁc T-cells, a dual ﬂuorescence–based
suppression assay was used. Regulation was ﬁrst assessed
in an autologous assay system, measuring the response of
PBMCs to recall antigen HA. Individual M.H. exhibited a
robust proliferative response to HA (9.6% of CD3
 PBMCs;
Fig. 3B). Addition of either T-cell clone MHB10.3 or its
epitope insulin B11–30 had little effect on proliferation
(Fig. 3C and D), whereas addition of MHB10.3 and its
epitope insulin B11–30 together resulted in complete sup-
pression of the HA-speciﬁc proliferative response (Fig.
3E). These data demonstrate that IL-10–secreting islet-
speciﬁc T-cells are potent regulators, and that regulation is
dependent on activation of Tregs by APC presentation of
cognate peptide. To pursue further analysis of the mech-
anisms of suppression, we used a panel of CD4
 Th1
clones speciﬁc for recall antigens TT and HA (RATT6 and
RAHA5, respectively). Both clones proliferate rapidly in
response to cognate antigen with 68 and 52% of cells
divided after 3 days, respectively (Fig. 4B and E). How-
ever, when cultured with MHB10.3 (Fig. 4C) or RAR5.3
(Fig. 4F) in the presence of the cognate islet peptide,
proliferation was dramatically reduced (33 and 16%), re-
sulting in suppression rates of 51 and 69%, respectively.
Blocking IL-10 and TGF- either individually or in combi-
nation had no effect on the ability of MHB10.3 or RAR5.3
to suppress proliferation of RATT6 (74–80% suppression,
Fig. 5A–H) or RAHA5 (51–59% suppression, Fig. 5I). This
absence of IL-10 dependency of regulation was also
present in studies in which Treg number and peptide
concentration were titrated to extinction of activity (sup-
plementary Fig. 3). Furthermore, blockade of IL-10 during
the activation and expansion of IL-10–secreting islet-
speciﬁc T-cell clones also did not affect the ability of the
cells to regulate (supplementary Fig. 4).
However, IL-10 secreted by these Tregs was found to
upregulate monocyte expression of the molecule B7-H4 (a
B7 family member that negatively regulates T-cell immu-
nity through inhibition of T-cell proliferation, cytokine
production, and cell cycle progression [21]), which is
inhibited by anti–IL-10R antibody (supplementary Fig. 5).
IL-10–secreting islet-speciﬁc Tregs require cell-cell
contact to mediate suppression. We used a transwell
system to investigate whether suppression by IL-10–se-
creting islet-speciﬁc Tregs is mediated by soluble factors
or dependent on cell-cell contact. When activated by
peptide, MHB10.3 is able to suppress proliferation of
RATT6 in coculture, but this is completely ablated if
responder and regulatory T-cells are physically separated
(Fig. 6A–D). The role of the APC in suppression was then
more closely investigated. First, a standard suppression
assay was established using irradiated PBMCs from a
donor with both HLA-DRB1*0301 and HLA-DRB1*0407
genotypes, which can therefore present antigens to both
regulatory (MHB10.3) and responder (RATT6) T-cell
clones (Fig. 6E and F). Second, assays were established
using irradiated PBMCs from two different donors (one
with the HLA-DRB1*0301 genotype but not HLA-
DRB1*0407 and another with the HLA-DRB1*0407 geno-
type but not HLA-DRB1*0301) in which presentation to
regulatory and responder clones is therefore separated on
two different APC populations (Fig. 6G and H). Whereas
suppression occurs when both responder and regulatory
T-cell clones are stimulated by the same APC (Fig. 6E and
F), no suppression is seen when presentation to regulatory
and responder clones takes place on two different APC
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FIG. 3. Regulation of autologous T-cell responses by MHB10.3. A–E: PBMCs from M.H. were labeled with CFSE and stimulated with combinations of
recombinant inﬂuenza hemagglutinin (HA; 45 ng/ml) and insulin B11–30 (10 g/ml) and in the presence or absence of DDAO-labeled MHB10.3
IL-10–secreting islet-speciﬁc T-cell clone as indicated. Proliferation of CD3
 T-cells was assessed after 6 days by ﬂow cytometry. Numbers represent
the percentage of CD3
 PBMCs in the gated area. Data are representative of more than three independent experiments. When activated by cognate
antigen, clone MHB10.3 completely abrogates the proliferative response of recall memory T-cells speciﬁc for HA. Ins, insulin; Tresp, T-cell responses.
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these latter cultures was observed at both high and low
levels of effector clone stimulation strength (supplemen-
tary Fig. 6). Similar assays were established using IL-10–
secreting islet-speciﬁc Treg RAR5.3 using two independent
responder T-cell clones and sources of APCs with identical
results (Fig. 6I and J).
IL-10–secreting islet-speciﬁc Tregs express cyto-
toxic molecules and kill islet antigen-presenting
cells. Because IL-10–secreting islet-speciﬁc Treg-medi-
ated suppression requires cell-cell contact and is not
mediated by cytokines conventionally associated with
regulation, we sought alternative mechanisms to account
for these effects. We noted that resting IL-10–secreting
islet-speciﬁc Treg clones express granzymes A and B and
perforin and that expression of perforin and granzyme B
was upregulated upon activation (supplementary Fig. 7).
To investigate whether expression of these cytotoxic
molecules translated into an ability to kill APCs, a ﬂow
cytometry–based cytotoxicity assay was used. High levels
of cytotoxicity were seen against APCs loaded with islet
autoantigen (56% at an effector/target ratios of 10:1),
whereas APCs lacking islet peptide were not killed, even
at high effector/target ratios (Fig. 7A). To investigate the
speciﬁcity of killing, a dual ﬂuorescence-intensity killing
assay was used. In this assay, peptide-pulsed and unpulsed
PBMCs were incubated in the same culture along with
IL-10–secreting islet-speciﬁc Tregs. In these experiments,
only peptide-loaded APCs (i.e., CD19
 B cells and CD14

monocytes) were killed (speciﬁc killing of 80 and 65%,
respectively), whereas APCs lacking islet peptide and
CD4
 T-cells were not killed despite juxtaposition with
highly activated Tregs in the cultures (Fig. 7B). To inves-
tigate the mechanism of killing, cells were preincubated
with inhibitors of the perforin pathway (ConA or EGTA) or
Fas/FasL ligand pathway (neutralizing anti-FasL antibody)
(Fig. 7C and D). Whereas killing was unaffected in the
presence of anti-FasL antibodies, it was completely abro-
gated in the presence of ConA or EGTA, demonstrating
that IL-10–speciﬁc islet-speciﬁc Tregs exhibit perforin-
granzyme–dependent cytotoxicity.
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MHB10.3 as indicated. D–F: The hemagglutinin-speciﬁc Th1 clone RAHA5 was labeled with CFSE and stimulated with combinations of
recombinant hemagglutinin (45 ng/ml) and IA-2 709–736 (25 g/ml) in the presence or absence of DDAO-labeled RAR5.3 as indicated.
HLA-matched DDAO-labeled irradiated PBMCs were used as a source of antigen-presenting cells. Proliferation of Th1 clones (DDAO
 cells) was
assessed after 3 days by ﬂow cytometry, and the gated regions represent the percentage of live clone cells that have undergone division.
Proliferation of the Th1 clones RATT6 and RAHA5 is suppressed by activated MHB10.3 and RAR5.3 Treg clones. Data are representative of a
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assays in which Tregs are activated by peptide-loaded
APCs, the responder T-cells undergoing regulation are not
themselves killed (supplementary Fig. 8). The kinetics of
suppression in relation to responder T-cell proliferation
are shown in supplementary Fig. 9 and demonstrate that
suppression is apparent and most potent when measured
at day 2 (the earliest time point at which proliferation of
responder T-cells can be detected; supplementary Fig. 9A).
Furthermore, if Tregs are placed in the APC/peptide
culture for 24 h prior to addition of the T responders
suppression is greatly enhanced, presumably due to killing
of most APCs before they have the chance to stimulate
responder T-cells (supplementary Fig. 9B–D).
IL-10–secreting islet autoantigen–speciﬁc Tregs ex-
press cytotoxic molecules directly ex vivo. To estab-
lish whether IL-10–secreting islet-speciﬁc Tregs express
cytotoxic molecules directly ex vivo, or gain this expres-
sion as a consequence of the cloning process in vitro, we
performed a multiplex RT-PCR on single IL-10
 CD4

T-cells freshly isolated from islet peptide–stimulated
PBMC cultures (Fig. 8). These experiments were per-
formed with the original donors used to clone MHB10.3
and RAR5.3 Tregs. All sorted T-cells were examined for
CD3 expression as a template quality control and also for
IL-10 expression. Only IL-10
 sorted T-cells that were also
IL-10 transcript–positive were included in the analysis.
These studies demonstrated that 67% (6/9) of the IL-10
transcript–positive T-cells expressed at least one cytotoxic
molecule, compared with 5.6% (1/18) of the IL-10 tran-
script–negative T-cells (P 
 0.0006).
DISCUSSION
The present study builds upon our previous observation
that in type 1 diabetes, a distinction can be made between
tolerant and disease states in terms of the polarization of
islet-speciﬁc CD4 T-cell responses. Notably, we previously
showed that islet autoreactive T-cells identiﬁed by IL-10
secretion are associated with both the nondiabetic state
and late onset disease. On this basis, we proposed that
IL-10 production by CD4 T-cells in response to islet
autoantigens represents a signature of immune regulation.
As proof of this concept, in the present study we report the
ﬁrst cloning of such human, IL-10–secreting islet-speciﬁc
T-cells (which we term ISIS-Tregs) and demonstrate that
their marked capacity for linked suppression of proinﬂam-
matory T-cells is associated with APC killing.
We ﬁrst screened a cohort of healthy individuals to
identify those with robust IL-10 polarization of islet auto-
reactive CD4 T-cell responses. In agreement with our
earlier studies, we found that the majority of nondiabetic
individuals mounted a signiﬁcant IL-10 response to at least
one islet autoantigen. We next used a sensitive, direct, ex
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FIG. 5. Regulation of clonal T-cell responses by IL-10–secreting islet-speciﬁc Tregs is not
dependent on IL-10 or TGF-. A–H: CFSE-labeled RATT6 and HLA-matched DDAO-
labeled irradiated PBMCs were stimulated with tetanus toxoid (100 ng/ml) and insulin
B11–30 (10 g/ml) in the absence (A–D) or presence (E–H) of DDAO-labeled MHB10.3
and monoclonal antibodies as indicated. Proliferation of RATT6 (DDAO
 cells) was
assessed after 3 days by ﬂow cytometry. Numbers indicate the percentage suppression in
the presence of MHB10.3. I: A similar experiment in which CFSE-labeled RAHA5,
DDAO-labeled RAR5.3, and HLA-matched DDAO-labeled irradiated PBMCs were stimu-
lated with either hemagglutinin (45 ng/ml) alone (black bars) or hemagglutinin and IA-2
709–736 (25 g/ml) (white bars) in the presence of monoclonal antibodies as indicated.
Proliferation of RAHA5 (DDAO
 cells) was assessed after 3 days by ﬂow cytometry.
Numbers indicate the percentage suppression in the presence of IA-2 709–736, and error
bars indicate SE from the mean for triplicate cultures. Data are representative of at least
three independent experiments.
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 cells) was assessed after 4 days by ﬂow cytometry. Numbers indicate percentage of suppression,
and error bars indicate SE from the mean for triplicate cultures.
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producing cells, to derive sufﬁcient numbers with which to
examine our original hypothesis that these cells have
regulatory properties. We demonstrate that not only are
IL-10–secreting islet-speciﬁc T-cells capable of suppress-
ing responses of resting CD4 memory T-cells present in
PBMC preparations, they are also potent suppressors of
both the proliferation and cytokine production of highly
activated Th1 T-cell clones similar to those believed to
play a role in the pathogenesis of type 1 diabetes. In
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incubated with various effector/target (E:T) ratios with resting RAR5.3 T-cells. Death of CFSE
 antigen-presenting cells was assessed by uptake
of 7-AAD. Similar results were obtained with MHB10.3. B: Autologous PBMCs from individual R.A. were labeled with either 0.1 mol/l CFSE and
pulsed with IA-2 709–736 or 1 mol/l CFSE and pulsed with DMSO diluent alone. After 3 h, excess peptide was removed by rigorous washing and
the peptide-pulsed, and unpulsed PBMCs were combined at a 1:1 ratio and incubated either alone or with resting RAR5.3 T-cells as indicated.
After incubation for 16 h at 37°C, cultures were harvested and death in different cell populations was assessed by multicolor ﬂow cytometry.
Numbers indicate percentage of speciﬁc death of peptide-pulsed cells in the gated population. C and D: Autologous PBMCs from individuals R.A.
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islet-speciﬁc Tregs (white bars) in the presence of inhibitors of cytotoxicity as indicated. After incubation for 16 h at 37°C, cultures were
harvested and death in different cell populations was assessed by multicolor ﬂow cytometry. Plots show percentage of viable CD19
 lymphocytes
that were peptide pulsed. Numbers indicate percentage of speciﬁc death of peptide-pulsed cells in the gated population, and error bars indicate
SE from the mean for triplicate cultures. Results indicate inhibition of APC killing by Tregs in the presence of inhibitors of cytotoxic granule
release. Data are representative of at least three independent experiments. ab, antibody.
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expanded populations of the prototypic polyclonal
CD4
CD127
loCD25
 naturally occurring Tregs (nTregs)
are able to suppress activated Th1 clones to such a degree
(J.L., personal communication). Further examination of
their function revealed that ISIS-Tregs have a highly
distinctive mode of action. Their ability to suppress effec-
tor T-cell function is mediated entirely independently of
production of cytokines or any other paracrine soluble
factors, requiring instead direct-cell contact. Using ISIS-
Treg and effector T-cell clones with differing HLA restric-
tion elements, we limited antigen presentation to occur on
the same APC or on two different APC populations.
Suppression was dependent on presentation of the cog-
nate antigen for both ISIS-Treg and effector T-cells on the
same APCs. In investigating the molecular and cellular
interactions required for this effect, we noted that ISIS-
Tregs express perforin and granzymes A and B and there-
fore examined the APC killing potential of these cells.
Only APCs bearing cognate antigen were killed by ISIS-
Tregs in a perforin-dependent manner, and as a result
APC-mediated activation of effector clones was effectively
negated. Critically, we conﬁrmed expression of perforin
and granzymes in freshly isolated ISIS-Tregs directly ex
vivo, excluding the possibility that their expression is an
artifact of clonal expansion in vitro.
Based on our studies in vitro, we hypothesize that in
vivo, ISIS-Tregs achieve regulation by a “kill the messen-
ger approach” in which APCs displaying high levels of
self-antigens are rapidly deleted, thus preventing the prim-
ing and/or expansion of potentially pathogenic autoreac-
tive CD4 T-helper and CD8 cytotoxic T-cells. We propose
a three-cell model of linked suppression in which profes-
sional APCs will display peptide-HLA complexes repre-
senting a range of autoantigens including insulin, IA-2, and
GAD-65 released by -cells (perhaps damaged by an
environmental insult such as a virus [22]). ISIS-Tregs will
kill these APCs, while sparing bystander APCs not display-
ing islet antigens. Although not providing “classical” anti-
gen-speciﬁc regulation (i.e., only regulating T-cells
responding to the same antigen), this mechanism provides
“tissue-speciﬁc” regulation, including suppression of T-
cells recognizing other islet autoantigens. Such a mecha-
nism of suppression has several important attributes, most
notably the highly speciﬁc nature and location of regula-
tion as a means of maintaining tissue-speciﬁc tolerance. In
sum, our data appear to support a model in which the most
potent regulatory function of these Tregs in vitro requires
cell-cell contact and is independent of IL-10. However, as
also pointed out by others in this ﬁeld (23,24) and sup-
ported by our ﬁnding in relation to B7-H4, we cannot
exclude the possibility that there are additional pathways
via IL-10 secretion through which ISIS-Tregs are able to
regulate in vivo and these remain to be elucidated.
Expression of cytotoxic molecules has been reported in
other natural and adaptive human polyclonal Treg popu-
lations (25–28). However, comparison with the highly
speciﬁc killing mediated by ISIS-Tregs is difﬁcult, as these
other Tregs are of unknown antigen speciﬁcity and require
polyclonal stimuli to mediate their suppressor function.
The importance of the cytotoxic function of Tregs has
recently been demonstrated in a model of transplantation
in which Tregs from granzyme B–deﬁcient mice were
unable to mediate transplant tolerance (29). Furthermore,
Benoist and colleagues have also highlighted the impor-
tance of a population of CD25
 Tregs characterized by the
expression of IL-10 and granzyme B in preventing disease
in a mouse model of type 1 diabetes (30), supporting the
suggestion that cytotoxic ISIS-Tregs may play an impor-
tant role in maintaining islet-speciﬁc tolerance in vivo.
At present, it is not possible to be certain where
ISIS-Tregs stand in the current, complex taxonomy of
regulatory T-cells. ISIS-Tregs share some features in com-
mon with other Treg populations (e.g., constitutive expres-
sion of CD25, FoxP3, CD39, and ICOS; requirement for
cell-cell contact to mediate suppression; and expression of
cytotoxic effector molecules) but not others (e.g., expres-
sion of GITR and absence of CD127), and the relevance of
these ﬁndings to their function and ontogeny will require
further investigation.
We speculate that ISIS-Tregs are generated in the pe-
riphery as a consequence of low-level exposure to autoan-
tigens occurring early during development or chronically,
in the absence of inﬂammatory signals, as has been
suggested for the generation of peripheral tolerance (31).
Intriguingly, ISIS-Tregs do bear striking similarities (IL-10
secretion and dependence on cell-cell contact) to Tregs
generated from naive cord blood cells by repeated stimu-
lation with immature allogeneic dendritic cells (32), sug-
gesting the possibility that ISIS-Tregs may be generated
early in development.
In summary, we have isolated and characterized a novel
population of human islet autoantigen–speciﬁc regulatory
T-cells associated with late development of type 1 diabe-
tes. These ISIS-Tregs are potent suppressors of Th1 effec-
tor cells and mediate suppression via direct contact with
autoantigen-presenting APCs, providing exquisite speciﬁc-
ity of suppression. This hitherto undescribed population of
antigen-speciﬁc Tregs, which appears to be constitutively
CD3 
IL-10 
RAR5.3
No cell
RA IL-10 +
RA IL-10 -
MHB10.3
MH IL-10 +
MH IL-10 -
Granzyme A 
Granzyme B 
Perforin 
FIG. 8. IL-10–producing islet-speciﬁc CD4
 T-cells express cytotoxic
molecules directly ex vivo. PBMCs from donors M.H. and R.A. were
stimulated with islet peptides, and after 48 h single CD4
 IL-10
 or
CD4
 IL-10
 T-cells isolated by ﬂow cytometry were deposited into
96-well plates containing 8 l lysis buffer. RT and ﬁrst-round PCR (30
cycles) were performed using gene-speciﬁc primers and the One Step
RT-PCR kit following the manufacturer’s instructions (Qiagen, Craw-
ley, U.K.). After multiplex RT-PCR, 1 l of a 1:100 dilution of the
reaction was used in individual gene, second round, nested PCRs (30
cycles) using internal primers and HotStar Taq Polymerase kit (Qia-
gen). Products were analyzed by agarose gel electrophoresis. Data
were considered for analysis only from cells that yielded a CD3
product. Each lane represents products ampliﬁed from a single cell. As
a positive control, pools of ﬁve cells of the clones RAR5.3 and MHB10.3
were used after peptide stimulation.
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provide a suitable target to strengthen tolerance to islets
by clinical immunointervention.
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